Therapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists,…mehr
Therapeutic Drug Monitoring: Newer Drugs and Biomarkers features timely topics such as the monitoring of classical and newer drugs, pharmacogenomics and the application of biomarkers in therapeutic drug monitoring. This reference also discusses the limitations of current commercially available immunoassays for therapeutic monitoring. It presents new and sophisticated techniques used for proper determination of blood levels and the clinical utility of therapeutic drug monitoring of contemporary drugs. Written by leading international experts and geared toward clinical pathologists, toxicologists, clinical chemists, laboratory professionals and physicians, this book is an essential resource on the current practice of therapeutic drug monitoring in improving patient safety.
Amitava Dasgupta received his Ph. D in chemistry from Stanford University and completed his fellowship training in Clinical Chemistry from the Department of Laboratory Medicine at the University of Washington School of Medicine at Seattle. He is board certified in both Toxicology and Clinical Chemistry by the American Board of Clinical Chemistry. Currently, he is a tenured Full Professor of Pathology and Laboratory Medicine at the University of Kansas Medical Center and Director of Clinical Laboratories at the University of Kansas Hospital. Prior to this appointment he was a tenured Professor of Pathology and Laboratory Medicine at the University of Texas McGovern medical School from February 1998 to April 2022. He has 252 papers to his credit. He is in the editorial board of four journals including Therapeutic Drug Monitoring, Clinica Chimica Acta, Archives of Pathology and Laboratory Medicine, and Journal of Clinical Laboratory Analysis.
Inhaltsangabe
Chapter 1. Introduction to Therapeutic Drug Monitoring: Frequently and Less Frequently Monitored Drugs
Chapter 2. Effects of Pre-Analytical Variables in Therapeutic Drug Monitoring
Chapter 3. Analytical Techniques used in Therapeutic Drug Monitoring
Chapter 4. Clinical Utility of Free Drug Monitoring
Chapter 5. Current Practice of Therapeutic Drug Monitoring: Dose Adjustment of Drugs using Pharmacokinetic models
Chapter 6. An Introduction to Personalized Medicine
Chapter 7. Application of Ultra-High Throughput Sequencing and Microarray Technologies in Pharmacogenomics Testing
Chapter 8. Pharmacogenomics and Warfarin therapy
Chapter 9. Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection: Example of Antibiotic Therapy Management
Chapter 10. Guidelines for Monitoring of Vancomycin, Aminoglycosides and certain antibiotics .
Chapter 11. Challenges in Therapeutic Drug Monitoring of Digoxin and other Antiarrhythmic Drugs
Chapter 12. Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants
Chapter 13. Challenges in Therapeutic Drug Monitoring of Classical Tricyclic and Newer Antidepressants: Analytical and Pharmacogenetics Considerations
Chapter14. Therapeutic Drug Monitoring of Selected Anticancer Drugs: Pharmacogenomics issues
Chapter 15. Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass Spectrometry
Chapter 16. Biomarkers: The Link between Therapeutic Drug Monitoring and Pharmacodynamics of Immunosuppressants
Chapter 17. Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Infection
Chapter 18. Drug Testing in Pain Management
Chapter 19. Role of Therapeutic Drug Monitoring to Identify Clinically Significant Drug-Herbal Supplement Interaction
